Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
17 5월 2024 - 8:30PM
Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the
Company will host the muscle biology-focused Contemporary
Landscapes in Muscle Biology Research Symposium (CLIMB) today, May
17th, 2024 at the Mission Bay Conference Center in San Francisco.
“We are proud to convene the CLIMB Research
Symposium, a unique forum for the muscle biology community,
including academic researchers and students, to engage in
scientific discussion and share innovative research,” said Fady I.
Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of
Research & Development. “As pioneers in the therapeutic
applications of muscle biology, we are driven to continuously push
the boundaries in the field and advance the understanding and
potential treatment of muscle-related diseases and disorders.
Through collaboration with academia and industry, we are committed
to driving transformative progress to shape the future of muscle
biology.”
CLIMB is a one-day research symposium bringing
together scientists, researchers and emerging professionals to
share innovative research in the field of muscle biology. The
symposium seeks to foster collaboration, facilitate networking
opportunities and promote interdisciplinary dialogue, with the
ultimate goal of driving advancements in the understanding and
treatment of muscle-related diseases and disorders. CLIMB will
feature distinguished expert speakers alongside poster
presentations of research in the field of muscle biology. Expert
speakers include:
- Eric Adler, M.D., FACC, Professor
of Medicine, The Czarina and Humberto S. Lopez Chancellors Endowed
Chair in Cardiology University of California, San Diego; Chief
Medical Officer, Lexeo Therapeutics
- Rachelle H. Crosbie, Ph.D.,
Professor and Chair, Integrative Biology and Physiology, University
of California Los Angeles
- Henk Granzier, Ph.D., Professor,
Cellular and Molecular Medicine, University of Arizona College of
Medicine Tucson
- Darren Hwee, Ph.D., Senior
Director, Pharmacology, Cytokinetics
- Ivan Luptak, M.D., Ph.D., Assistant
Professor, Medicine, Boston University Chobanian and Avedisian
School of Medicine
- Katie Pollard, Ph.D., L.K. Whittier
Director, Gladstone Institute of Data Science and Biotechnology;
Professor, Department of Epidemiology and Biostatistics, UC San
Francisco; Investigator, Chan Zuckerberg Biohub San Francisco
- Benjamin L. Prosser, Ph.D.,
Associate Professor of Physiology, Associate Director, Pennsylvania
Muscle Institute, Director, Center for Epilepsy and
NeuroDevelopmental Disorders, University of Pennsylvania Perelman
School of Medicine
- Deepak Srivastava, M.D., President
and Senior Investigator, Gladstones Institutes
- Sharif Tabebordbar, Ph.D.,
Co-Founder and Chief Scientific Officer, Kate Therapeutics
About Cytokinetics
Cytokinetics is a late-stage, specialty
cardiovascular biopharmaceutical company focused on discovering,
developing and commercializing first-in-class muscle activators and
next-in-class muscle inhibitors as potential treatments for
debilitating diseases in which cardiac muscle performance is
compromised. As a leader in muscle biology and the mechanics of
muscle performance, the company is developing small molecule drug
candidates specifically engineered to impact myocardial muscle
function and contractility. Cytokinetics is preparing for
regulatory submissions for aficamten, its next-in-class cardiac
myosin inhibitor, following positive results from SEQUOIA-HCM, the
pivotal Phase 3 clinical trial in obstructive hypertrophic
cardiomyopathy. Aficamten is also currently being evaluated in
MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy
compared to metoprolol as monotherapy in patients with obstructive
HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients
with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten
in a pediatric population with obstructive HCM, and FOREST-HCM, an
open-label extension clinical study of aficamten in patients with
HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac
muscle activator, in patients with heart failure. Additionally,
Cytokinetics is developing CK-586, a cardiac myosin inhibitor with
a mechanism of action distinct from aficamten for the potential
treatment of HFpEF, and CK-136, a cardiac troponin activator for
the potential treatment HFrEF and other types of heart failure,
such as right ventricular failure resulting from impaired cardiac
contractility.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Act’s Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements express or implied relating to the
properties or potential benefits of aficamten or any of our other
drug candidates and our ability to obtain regulatory approval for
aficamten for the treatment of obstructive hypertrophic
cardiomyopathy or any other indication from FDA or any other
regulatory body in the United States or abroad. Such statements are
based on management’s current expectations, but actual results may
differ materially due to various risks and uncertainties,
including, but not limited to the risks related to Cytokinetics’
business outlines in Cytokinetics’ filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and Cytokinetics’ actual results
of operations, financial condition and liquidity, and the
development of the industry in which it operates, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements
that Cytokinetics makes in this press release speak only
as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are
registered trademarks of Cytokinetics in the U.S. and certain other
countries.
Contact:Cytokinetics Diane
WeiserSenior Vice President, Corporate Affairs(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Cytokinetics (NASDAQ:CYTK)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024